Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (8101)	4/2/2003 12:38:26 AM
From: BulbaMan	Respond to of 52153

And the guy doesn't even mention the war!

To: tuck who wrote (8101)	4/2/2003 9:46:21 AM
From: Biomaven	Respond to of 52153

tuck, Thanks for the article. Be great if you can post the link to the follow-up article discussing valuation. My own view is pretty different - biotech is showing excellent relative strength here, lead by the profitable first-tier companies. With these tier-1 companies projecting 20+% earnings growth for the next three/four years with little regulatory risk, I can't see the overall weakness he projects. Note for example the increased projections by BGEN today (I own a little). Peter